TAIJI GROUP: Received the clinical trial approval notice for Semaglutide injection
I'm PortAI, I can summarize articles.
TAIJI GROUP's wholly-owned subsidiary Fuling Pharmaceutical Factory recently received approval from the National Medical Products Administration to conduct clinical trials for Semaglutide injection, indicated for type 2 diabetes. This medication is a long-acting GLP-1 receptor agonist that stimulates insulin production, inhibits glucagon secretion, and reduces appetite, assisting in weight management
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments